Clinical Trial Update: ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) [Phase 3]

View source ↗

Summary

Phase 3 trial ENHANCE evaluating seladelpar in patients with primary biliary cholangitis who had inadequate response to or intolerance of UDCA; trial completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Seladelpar (seladelpar)

Snippet

Sponsor: Gilead Sciences | Conditions: Primary Biliary Cholangitis | Phase 3 | Status: COMPLETED | Results posted: 2022-05-31